CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.

ABSTRACT:

Background

The gene encoding the target of calcium channel blockers, the alpha1c-subunit of the L-type calcium channel (CACNA1C), has not been well characterized, and only small pharmacogenetic studies testing this gene have been published to date.

Methods and results

Resequencing of CACNA1C was performed followed by a nested case-control study of the INternational VErapamil SR/trandolapril STudy (INVEST) GENEtic Substudy (INVEST-GENES). Of 46 polymorphisms identified, 8 were assessed in the INVEST-GENES. Rs1051375 was found to have a significant interaction with treatment strategy (P=0.0001). Rs1051375 A/A genotype was associated with a 46% reduction in the primary outcome among those randomized to verapamil SR treatment, when compared with atenolol treatment (odds ratio 0.

SUBMITTER: Beitelshees AL 

PROVIDER: S-EPMC2761685 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature